Clinical Trials
1,797 trialsNivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
ADAPT NXT
argenx
MK-4280A-007
Merck Sharp & Dohme LLC
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Children's Oncology Group
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Alliance for Clinical Trials in Oncology
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
MEN-301
NX Development Corp
Viale-a
AbbVie
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
BELINDA
Novartis
SERENE
Sumitomo Pharma Switzerland GmbH
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
CAPTRANE
Institut Cancerologie de l'Ouest
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Merck Sharp & Dohme LLC
KEYLYNK-001
Merck Sharp & Dohme LLC
ZEAL-1L
GlaxoSmithKline
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Children's Oncology Group
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
KEYNOTE-991
Merck Sharp & Dohme LLC
KEYNOTE-937
Merck Sharp & Dohme LLC
COMBI-AD
Novartis
FLAURA
AstraZeneca
INFINITE
Ferring Ventures Limited
NAPOLI 3
Ipsen
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
KEYNOTE-966
Merck Sharp & Dohme LLC
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
SKYSCRAPER-08
Hoffmann-La Roche
VIALE-M
AbbVie
V503-024
Merck Sharp & Dohme LLC
SKYSCRAPER-02
Hoffmann-La Roche
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
KEYNOTE-966
Merck Sharp & Dohme LLC
TRANSFORM-1
AbbVie
MK-3475-775
Eisai Inc.
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
PEARLS
Merck Sharp & Dohme LLC
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
Merck Sharp & Dohme LLC
KEYNOTE-564
Merck Sharp & Dohme LLC
KEYNOTE-630
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group